Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage 2 hypertension inadequately controlled by monotherapy

Clinical Drug Investigation

Volumn 25, Issue 7, 2005, Pages 445-451

  Rubio Guerra, Alberto Francisco ^a,b,c   Arceo Navarro, Adalberto ^a   Lozano Nuevo, José Juan ^a   Vargas Ayala, Germán ^a   Rodríguez López, Leticia ^a   Ramos Brizuela, Luz María ^a  

^a Hospital General de Ticoman SS DF   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; TRANDOLAPRIL PLUS VERAPAMIL;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEVICE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MEDICAL RECORD; MEXICO; MONOTHERAPY; PRIORITY JOURNAL; SELF EXAMINATION; TREATMENT OUTCOME;

EID: 22544435223     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525070-00003     Document Type: Article

References (11)

1. Mallion JM, Carreta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003; 12 Suppl. 1: 36-43
2. The Seventh Report of the Joint National Committee on Detec tion, Evaluation, and Treatment of High Blood Pressure. JNC 7. Complete version. Hypertension 2003; 42: 1206-52
3. Jamerson K, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control com pared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17: 495-501
4. Punzi HA, Novrit BA. The treatment of severe hypertension with trandolapril, verapamil and hydrochlorothiazide. J Hum Hypertens 1997; 11: 477-81
5. Pepine CJ, Handberg EM, Cooper-Dehoff R, et al. A calcium antagonist versus a non-calcium antagonist hypertension-treatment strategy for patients with coronary artery disease (INVEST). JAMA 2003; 290: 2805-16
6. Rubio AF, Trevĩno CJ, Vargas G, et al. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest 2002; 22: 541-6
7. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
8. Rubio AF, Arceo A, Vargas G, et al. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004; 27: 1688-91
9. Aepfelbacher FC, Messerli FH, Nunez E. Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Am J Cardiol 1997; 79: 826-8
10. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-31
11. Velásquez O, Rosas M, Lara A, et al. Hipertensión arterial en México, Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002; 72: 71-84